Cost-utility analysis of Palbociclib + letrozole and ribociclib + letrozole versus Letrozole monotherapy in the first-line treatment of metastatic breast cancer in Iran using partitioned survival model
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Cost-utility analysis of Palbociclib + letrozole and ribociclib + letrozole versus Letrozole monotherapy in the first-line treatment of metastatic breast cancer in Iran using partitioned survival model ; volume:13 ; number:1 ; day:9 ; month:11 ; year:2023 ; pages:1-13 ; date:12.2023
Health economics review ; 13, Heft 1 (9.11.2023), 1-13, 12.2023
- Urheber
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13561-023-00463-6
- URN
-
urn:nbn:de:101:1-2024012911090304720399
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:32 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Darvishi, Ali
- Daroudi, Rajabali
- Fazaeli, Ali Akbar
- SpringerLink (Online service)
Ähnliche Objekte (12)
Real-World Tumor Response of Palbociclib Plus Letrozole Versus Letrozole for Metastatic Breast Cancer in US Clinical Practice
The early days of letrozole
A decade of letrozole: FACE
Letrozole in Male Breast Cancer
Letrozole and Palbociclib in Advanced Breast Cancer: Outcome from Cancer Institute, Chennai
Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2− metastatic breast cancer in US real-world clinical practice
Expanded Access Study of Palbociclib Plus Letrozole for Postmenopausal Women with HR+/HER2− Advanced Breast Cancer in Latin America for Whom Letrozole Therapy is Deemed Appropriate
Letrozole in the extended adjuvant setting: MA.17
Correction: Expanded Access Study of Palbociclib Plus Letrozole for Postmenopausal Women with HR+/HER2− Advanced Breast Cancer in Latin America for Whom Letrozole Therapy is Deemed Appropriate
The discovery and mechanism of action of letrozole
Letrozole sensitizes breast cancer cells to ionizing radiation
Letrozole in advanced breast cancer: the PO25 trial
Real-World Tumor Response of Palbociclib Plus Letrozole Versus Letrozole for Metastatic Breast Cancer in US Clinical Practice
The early days of letrozole
A decade of letrozole: FACE
Letrozole in Male Breast Cancer
Letrozole and Palbociclib in Advanced Breast Cancer: Outcome from Cancer Institute, Chennai
Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2− metastatic breast cancer in US real-world clinical practice
Expanded Access Study of Palbociclib Plus Letrozole for Postmenopausal Women with HR+/HER2− Advanced Breast Cancer in Latin America for Whom Letrozole Therapy is Deemed Appropriate
Letrozole in the extended adjuvant setting: MA.17
Correction: Expanded Access Study of Palbociclib Plus Letrozole for Postmenopausal Women with HR+/HER2− Advanced Breast Cancer in Latin America for Whom Letrozole Therapy is Deemed Appropriate
The discovery and mechanism of action of letrozole
Letrozole sensitizes breast cancer cells to ionizing radiation
Letrozole in advanced breast cancer: the PO25 trial
Real-World Tumor Response of Palbociclib Plus Letrozole Versus Letrozole for Metastatic Breast Cancer in US Clinical Practice
The early days of letrozole
A decade of letrozole: FACE
Letrozole in Male Breast Cancer
Letrozole and Palbociclib in Advanced Breast Cancer: Outcome from Cancer Institute, Chennai
Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2− metastatic breast cancer in US real-world clinical practice
Expanded Access Study of Palbociclib Plus Letrozole for Postmenopausal Women with HR+/HER2− Advanced Breast Cancer in Latin America for Whom Letrozole Therapy is Deemed Appropriate
Letrozole in the extended adjuvant setting: MA.17
Correction: Expanded Access Study of Palbociclib Plus Letrozole for Postmenopausal Women with HR+/HER2− Advanced Breast Cancer in Latin America for Whom Letrozole Therapy is Deemed Appropriate
The discovery and mechanism of action of letrozole
Letrozole sensitizes breast cancer cells to ionizing radiation